Skip to main content
Premium Trial:

Request an Annual Quote

TransDerm Looks Past RNAi for Next Clinical Candidate


TransDerm, a small biotech focused on developing a treatment for pachyonychia congenita (PC), has just kicked off a phase I trial of a new drug candidate designed to treat the rare skin condition.

However, while the company had been focused on using RNAi as foundation for its products, the new trial is testing a product based on sirolimus, a macrolide immunosuppressant commonly used to prevent organ rejection in transplant patients.

TransDerm's first candidate, the siRNA-based drug TD101, proved capable of treating the lesions caused by PC in a single-patient phase I trial in 2008, but administration of the therapy — injection via a standard hypodermic needle — proved too painful to make the approach viable.

TransDerm began developing a microneedle array that could deliver TD101 without the pain and had been planning to begin testing it in another clinical study. However, it appears that the company has opted to pursue a different therapeutic modality for its next clinical candidate in sirolimus, which is topically administered.

It is unclear why TransDerm has put its TD101 efforts on hold, and company officials were unavailable for comment. However, the agent was designed to target a specific genetic mutation that is only present in a fraction of PC patients — a limit to its use that may have prompted the move to a compound with a potentially broader spectrum of activity.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.